<code id='30DBD3189E'></code><style id='30DBD3189E'></style>
    • <acronym id='30DBD3189E'></acronym>
      <center id='30DBD3189E'><center id='30DBD3189E'><tfoot id='30DBD3189E'></tfoot></center><abbr id='30DBD3189E'><dir id='30DBD3189E'><tfoot id='30DBD3189E'></tfoot><noframes id='30DBD3189E'>

    • <optgroup id='30DBD3189E'><strike id='30DBD3189E'><sup id='30DBD3189E'></sup></strike><code id='30DBD3189E'></code></optgroup>
        1. <b id='30DBD3189E'><label id='30DBD3189E'><select id='30DBD3189E'><dt id='30DBD3189E'><span id='30DBD3189E'></span></dt></select></label></b><u id='30DBD3189E'></u>
          <i id='30DBD3189E'><strike id='30DBD3189E'><tt id='30DBD3189E'><pre id='30DBD3189E'></pre></tt></strike></i>

          entertainment

          entertainment

          author:hotspot    Page View:69
          The cost of healthcare health technology assessment
          APStock

          Physicians are in line to absorb more Medicare cuts next year, while hospital outpatient departments and surgery centers will get billions in new revenue.

          The base figure that determines how much physicians get paid by Medicare will decrease by 3.3% for 2024, the federal government said Thursday.

          advertisement

          The cuts will not be distributed equally among all specialties. Indeed, primary care doctors, endocrinologists, nurse practitioners, and physician assistants would see their Medicare payment rates rise, on average, according to the annual payment rule. Cuts would be steepest for all types of radiologists, including interventionalists and nuclear medicine, as well as vascular surgeons.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Apple is now the first public company to be valued at $3 trillion
          Apple is now the first public company to be valued at $3 trillion

          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

          read more
          In key trial, Verve's treatment lowers cholesterol levels in patients
          In key trial, Verve's treatment lowers cholesterol levels in patients

          APStockVerveTherapeuticssaidSundaythatthefirst10peopletoreceiveaone-timetreatmentpoweredbyaformofCRI

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

          INAFASSBENDER/AFPviaGettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup tog